Structural Basis and Kinetic Pathway of RBM39 Recruitment to DCAF15 by a Sulfonamide Molecular Glue E7820 von Du, Xinlin, Volkov, Oleg A., Czerwinski, Robert M., Tan, HuiLing, Huerta, Carlos, Morton, Emily R., Rizzi, Jim P., Wehn, Paul M., Xu, Rui, Nijhawan, Deepak, Wallace, Eli M.

Volltext

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma von Courtney, Kevin D, Infante, Jeffrey R, Lam, Elaine T, Figlin, Robert A, Rini, Brian I, Brugarolas, James, Zojwalla, Naseem J, Lowe, Ann M, Wang, Keshi, Wallace, Eli M, Josey, John A, Choueiri, Toni K

Volltext

On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models von Cho, Hyejin, Du, Xinlin, Rizzi, James P., Liberzon, Ella, Chakraborty, Abhishek A., Gao, Wenhua, Carvo, Ingrid, Signoretti, Sabina, Bruick, Richard K., Josey, John A., Wallace, Eli M., Kaelin, William G.

Volltext

Targeting renal cell carcinoma with a HIF-2 antagonist von Chen, Wenfang, Hill, Haley, Christie, Alana, Kim, Min Soo, Holloman, Eboni, Pavia-Jimenez, Andrea, Homayoun, Farrah, Ma, Yuanqing, Patel, Nirav, Yell, Paul, Hao, Guiyang, Yousuf, Qurratulain, Joyce, Allison, Pedrosa, Ivan, Geiger, Heather, Zhang, He, Chang, Jenny, Gardner, Kevin H., Bruick, Richard K., Reeves, Catherine, Hwang, Tae Hyun, Courtney, Kevin, Frenkel, Eugene, Sun, Xiankai, Zojwalla, Naseem, Wong, Tai, Rizzi, James P., Wallace, Eli M., Josey, John A., Xie, Yang, Xie, Xian-Jin, Kapur, Payal, McKay, Renée M., Brugarolas, James

Volltext

3‑[(1S,2S,3R)‑2,3-Difluoro-1-hydroxy-7-methylsulfonyl­indan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell... von Xu, Rui, Wang, Keshi, Rizzi, James P, Huang, Heli, Grina, Jonas A, Schlachter, Stephen T, Wang, Bin, Wehn, Paul M, Yang, Hanbiao, Dixon, Darryl D, Czerwinski, Robert M, Du, Xinlin, Ged, Emily L, Han, Guangzhou, Tan, Huiling, Wong, Tai, Xie, Shanhai, Josey, John A, Wallace, Eli M

Volltext

A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma von Wallace, Eli M, Rizzi, James P, Han, Guangzhou, Wehn, Paul M, Cao, Zhaodan, Du, Xinlin, Cheng, Tzuling, Czerwinski, Robert M, Dixon, Darryl D, Goggin, Barry S, Grina, Jonas A, Halfmann, Megan M, Maddie, Melissa A, Olive, Sarah R, Schlachter, Stephen T, Tan, Huiling, Wang, Bin, Wang, Keshi, Xie, Shanhai, Xu, Rui, Yang, Hanbiao, Josey, John A

Volltext

Suppression of HIF2 signalling attenuates the initiation of hypoxia-induced pulmonary hypertension von Hu, Cheng-Jun, Poth, Jens M, Zhang, Hui, Flockton, Amanda, Laux, Aya, Kumar, Sushil, McKeon, Brittany, Mouradian, Gary, Li, Min, Riddle, Suzette, Pugliese, Steven C, Brown, R Dale, Wallace, Eli M, Graham, Brian B, Frid, Maria G, Stenmark, Kurt R

Volltext

Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate (S)‑3-((2,2-Di... von Wehn, Paul M, Rizzi, James P, Dixon, Darryl D, Grina, Jonas A, Schlachter, Stephen T, Wang, Bin, Xu, Rui, Yang, Hanbiao, Du, Xinlin, Han, Guangzhou, Wang, Keshi, Cao, Zhaodan, Cheng, Tzuling, Czerwinski, Robert M, Goggin, Barry S, Huang, Heli, Halfmann, Megan M, Maddie, Melissa A, Morton, Emily L, Olive, Sarah R, Tan, Huiling, Xie, Shanhai, Wong, Tai, Josey, John A, Wallace, Eli M

Volltext

Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate ( S)-3-((2,2-D... von Wehn, Paul M, Rizzi, James P, Dixon, Darryl D, Grina, Jonas A, Schlachter, Stephen T, Wang, Bin, Xu, Rui, Yang, Hanbiao, Du, Xinlin, Han, Guangzhou, Wang, Keshi, Cao, Zhaodan, Cheng, Tzuling, Czerwinski, Robert M, Goggin, Barry S, Huang, Heli, Halfmann, Megan M, Maddie, Melissa A, Morton, Emily L, Olive, Sarah R, Tan, Huiling, Xie, Shanhai, Wong, Tai, Josey, John A, Wallace, Eli M

Volltext

Targeting HIF2 alpha-ARNT hetero-dimerisation as a novel therapeutic strategy for pulmonary arterial hypertension von Macias, David, Moore, Stephen, Crosby, Alexi, Southwood, Mark, Du, Xinlin, Tan, Huiling, Xie, Shanhai, Vassallo, Arlette, Wood, Alexander J. T., Wallace, Eli M., Cowburn, Andrew S.

Volltext

Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors von Blake, James F, Xu, Rui, Bencsik, Josef R, Xiao, Dengming, Kallan, Nicholas C, Schlachter, Stephen, Mitchell, Ian S, Spencer, Keith L, Banka, Anna L, Wallace, Eli M, Gloor, Susan L, Martinson, Matthew, Woessner, Richard D, Vigers, Guy P.A, Brandhuber, Barbara J, Liang, Jun, Safina, Brian S, Li, Jun, Zhang, Birong, Chabot, Christine, Do, Steven, Lee, Leslie, Oeh, Jason, Sampath, Deepak, Lee, Brian B, Lin, Kui, Liederer, Bianca M, Skelton, Nicholas J

Volltext

Discovery and preclinical development of AR453588 as an anti-diabetic glucokinase activator von Hinklin, Ronald J., Baer, Brian R., Boyd, Steven A., Chicarelli, Mark D., Condroski, Kevin R., DeWolf, Walter E., Fischer, John, Frank, Michele, Hingorani, Gary P., Lee, Patrice A., Neitzel, Nickolas A., Pratt, Scott A., Singh, Ajay, Sullivan, Francis X., Turner, Timothy, Voegtli, Walter C., Wallace, Eli M., Williams, Lance, Aicher, Thomas D.

Volltext

Lead change of a HIF-2α antagonist guided by multiparameter optimization and utilization of an Olp→πAr interaction von Wehn, Paul M., Yang, Song, Grina, Jonas A., Rizzi, James P., Schlachter, Stephen T., Wang, Bin, Xu, Rui, Yang, Hanbiao, Du, Xinlin, Han, Guangzhou, Wang, Keshi, Czerwinski, Robert M., Ged, Emily L., Huang, Heli, Halfmann, Megan M., Maddie, Melissa A., Morton, Emily R., Olive, Sarah R., Tan, Huiling, Xie, Shanhai, Josey, John A., Wallace, Eli M.

Volltext

Total Synthesis of the Pseudopterane (.+-.)-Kallolide B von Marshall, James A, Wallace, Eli M, Coan, Paul S

Volltext

Small Molecule HIF‐2α Antagonists and Their Therapeutic Applications von Wallace, Eli M.

Volltext

Design and Synthesis of Potent, Selective Inhibitors of Endothelin-Converting Enzyme von Wallace, Eli M, Moliterni, John A, Moskal, Michael A, Neubert, Alan D, Marcopulos, Nicholas, Stamford, Lisa B, Trapani, Angelo J, Savage, Paula, Chou, Mary, Jeng, Arco Y

Volltext

Synthetic Routes to Allenic Acids and Esters and Their Stereospecific Conversion to Butenolides von Marshall, James A, Wolf, Mark A, Wallace, Eli M

Volltext

Discovery of spirocyclic sulfonamides as potent Akt inhibitors with exquisite selectivity against PKA von Xu, Rui, Banka, Anna, Blake, James F., Mitchell, Ian S., Wallace, Eli M., Bencsik, Josef R., Kallan, Nicholas C., Spencer, Keith L., Gloor, Susan L., Martinson, Matthew, Risom, Tyler, Gross, Stefan D., Morales, Tony H., Wu, Wen-I, Vigers, Guy P.A., Brandhuber, Barbara J., Skelton, Nicholas J.

Volltext

Potent and Selective Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors. 1. 4-(4-Bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones von Wallace, Eli M, Lyssikatos, Joseph, Blake, James F, Seo, Jeongbeob, Yang, Hong Woon, Yeh, Tammie C, Perrier, Michele, Jarski, Heidi, Marsh, Vivienne, Poch, Gregory, Livingston, Michelle Goyette, Otten, Jennifer, Hingorani, Gary, Woessner, Rich, Lee, Patrice, Winkler, James, Koch, Kevin

Volltext

Potent and Selective Non-Peptidic Inhibitors of Endothelin-Converting Enzyme-1 with Sustained Duration of Action von De Lombaert, Stéphane, Blanchard, Louis, Stamford, Lisa B, Tan, Jenny, Wallace, Eli M, Satoh, Yoshitaka, Fitt, John, Hoyer, Denton, Simonsbergen, David, Moliterni, John, Marcopoulos, Nicholas, Savage, Paula, Chou, Mary, Trapani, Angelo J, Jeng, Arco Y

Volltext